Preventative Treatment for Migraine Patients

CE / CME

Personalized Migraine Prevention: Crafting Proactive Treatment Plans through Shared Decision-Making

Physician Assistants/Physician Associates: 0.50 AAPA Category 1 CME credit

Nurses: 0.50 Nursing contact hour

Physicians: maximum of 0.50 AMA PRA Category 1 Credit

Pharmacists: 0.50 contact hour (0.05 CEUs)

Released: May 28, 2024

Expiration: May 27, 2025

Activity

Progress
1 2
Course Completed

Alice decides to start OnabotulinumtoxinA for chronic migraine prevention and returns for a follow-up after 6 months. She is quite happy with the decrease in frequency and severity of her migraine attacks and reports currently having 8 migraine days per month. She continues to use a triptan and gepant combination for acute treatment. She asks about other options to consider as she is still having 8 migraine attacks per month, some of which are debilitating. You discuss with her the different CGRP-targeted therapy options for prevention.

Which of the following statements about CGPR-targeted therapies is true?